Metformina Placasod

Metformin, the active ingredient in Metformina Placasod, is a biguanide presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, where it helps to lower elevated blood glucose levels by improving insulin sensitivity and reducing hepatic glucose output.

GNH USA supplies Metformina Placasod as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support safe import and distribution across global markets.

Metformina Placasod is a biguanide antidiabetic that acts on glucose metabolism pathways. - Type 2 diabetes mellitus: improves overall glycemic control in adult patients. - Adjunct to diet and exercise in type 2 diabetes: lowers fasting plasma glucose when lifestyle measures alone are insufficient. - Prevention of progression from impaired glucose tolerance to type 2 diabetes: delays onset in high‑risk adults.

Metformina Placasod may cause a range of adverse reactions, most of which are related to the gastrointestinal system or metabolic disturbances.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Diarrhea: frequent loose stools, often transient. - Abdominal discomfort: cramping or pain in the abdomen. - Metallic taste: a persistent metallic sensation in the mouth. - Loss of appetite: reduced desire to eat. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening buildup of lactic acid. - Severe hypoglycemia: especially when combined with other antidiabetic agents. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or swelling. - Vitamin B12 deficiency: long‑term therapy may reduce absorption.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications. - Renal function: assess creatinine clearance and avoid use in severe renal impairment. - Hepatic function: evaluate liver enzymes, as dysfunction may increase risk of lactic acidosis. - Age considerations: start at lower doses in elderly patients and monitor tolerance. - Alcohol intake: advise patients to limit alcohol, which can potentiate lactic acidosis. - Concomitant medications: review for drugs that may affect renal function or increase metformin levels. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Metformina Placasod can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase risk of lactic acidosis. - Cimetidine: can raise plasma metformin concentrations, heightening toxicity risk.

Moderate Interactions (Monitor Closely): - Alcohol: enhances risk of lactic acidosis. - Diuretics: may affect renal clearance of metformin. - Corticosteroids: can raise blood glucose, requiring dose adjustments. - Beta‑blockers: may mask hypoglycemia symptoms. - Other antidiabetic agents (e.g., sulfonylureas): increase likelihood of hypoglycemia.